AstraZeneca PLC (AZN)vsIntuitive Surgical Inc (ISRG)
AZN
AstraZeneca PLC
$186.85
-0.22%
HEALTHCARE · Cap: $263.78B
ISRG
Intuitive Surgical Inc
$468.52
-3.36%
HEALTHCARE · Cap: $152.62B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 430% more annual revenue ($61.37B vs $11.58B). ISRG leads profitability with a 25.5% profit margin vs 17.0%. AZN appears more attractively valued with a PEG of 1.22. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
ISRG
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$186.85
$8.11 discount
Margin of Safety
+78.3%
Fair Value
$1989.68
Current Price
$468.52
$1521.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Strong operational efficiency at 33.3%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 26 of every $100 in revenue as profit
Revenue surging 21.7% year-over-year
Generating 1.1B in free cash flow
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
Trading at 10.2x book value
Premium valuation, high expectations priced in
Earnings declined 23.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : ISRG
The strongest argument for ISRG centers on Operating Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 25.5% and operating margin at 33.3%. Revenue growth of 21.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : ISRG
The primary concerns for ISRG are PEG Ratio, Price/Book, P/E Ratio. A P/E of 52.2x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a mature stock while ISRG is a growth play — different risk/reward profiles.
ISRG carries more volatility with a beta of 1.46 — expect wider price swings.
ISRG is growing revenue faster at 21.7% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 58/100), backed by strong 17.0% margins. ISRG offers better value entry with a 78.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Intuitive Surgical Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?